Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 93

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Pseudomonas aeruginosa: Recent Advances in Vaccine Development

Killough, Matthew, Rodgers, Aoife, Ingram, Rebecca·2022·Vaccines

Abstract

Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines10071100

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 118

  1. Mulani, 2019, Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review, Front. Microbiol., 10, 539, 10.3389/fmicb.2019.00539 · DOI · Paper page
  2. Founou, R.C., Founou, L.L., and Essack, S.Y. (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PLoS ONE, 12. · DOI · Paper page
  3. Moradali, 2017, Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence, Front. Cell. Infect. Microbiol., 7, 39, 10.3389/fcimb.2017.00039 · DOI · Paper page
  4. Jurado-Martín, I., Sainz-Mejías, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22. · DOI · Paper page
  5. Barken, 2008, Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms, Environ. Microbiol., 10, 2331, 10.1111/j.1462-2920.2008.01658.x · DOI · Paper page
  6. Deveaux, W., and Selvarajoo, K. (2019). Searching for simple rules in Pseudomonas aeruginosa biofilm formation. BMC Res. Notes, 12. · doi:10.1186/s13104-019-4795-x
  7. Thi, M.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21. · DOI · Paper page
  8. Moser, 2021, Immune Responses to Pseudomonas aeruginosa Biofilm Infections, Front. Immunol., 12, 625597, 10.3389/fimmu.2021.625597 · DOI · Paper page
  9. Zgurskaya, 2020, Molecular characterization of the outer membrane of Pseudomonas aeruginosa, Biochim. Et Biophys. Acta (BBA) Biomembr., 1862, 183151, 10.1016/j.bbamem.2019.183151 · DOI
  10. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies, Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  11. Breidenstein, 2011, Pseudomonas aeruginosa: All roads lead to resistance, Trends Microbiol., 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
  12. Bisht, 2020, Pseudomonas aeruginosa polymicrobial interactions during lung infection, Curr. Opin. Microbiol., 53, 1, 10.1016/j.mib.2020.01.014 · DOI
  13. Raman, 2018, Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis, Antimicrob. Resist. Infect. Control, 7, 79, 10.1186/s13756-018-0370-9 · DOI · Paper page
  14. Coates, M., Blanchard, S., and MacLeod, A.S. (2018). Innate antimicrobial immunity in the skin: A protective barrier against bacteria, viruses, and fungi. PLOS Pathog., 14. · DOI
  15. Elmassry, 2020, New markers for sepsis caused by Pseudomonas aeruginosa during burn infection, Metabolomics, 16, 40, 10.1007/s11306-020-01658-2 · DOI
  16. Mahar, 2010, Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes, Burns, 36, 1228, 10.1016/j.burns.2010.05.009 · doi:10.1016/j.burns.2010.05.009
  17. Weintrob, 2018, Early Infections Complicating the Care of Combat Casualties from Iraq and Afghanistan, Surg. Infect., 19, 286, 10.1089/sur.2017.240 · DOI
  18. Kollef, 2014, Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa, Crit. Care Med., 42, 2178, 10.1097/CCM.0000000000000510 · DOI · Paper page
  19. Pitiriga, 2020, Central venous catheter-related bloodstream infection and colonization: The impact of insertion site and distribution of multidrug-resistant pathogens, Antimicrob. Resist. Infect. Control, 9, 189, 10.1186/s13756-020-00851-1 · DOI
  20. Olejnickova, 2014, Catheter-related infections caused by Pseudomonas aeruginosa: Virulence factors involved and their relationships, Pathog. Dis., 72, 87
  21. Safdar, 2005, Clinical and economic consequences of ventilator-associated pneumonia: A systematic review, Crit. Care Med., 33, 2184, 10.1097/01.CCM.0000181731.53912.D9 · DOI · Paper page
  22. Mehta, 2020, Bronchoscope-Related “Superbug” Infections, Chest, 157, 454, 10.1016/j.chest.2019.08.003 · doi:10.1016/j.chest.2019.08.003
  23. Baidya, 2021, Biofilm Formation by Pathogens Causing Ventilator-Associated Pneumonia at Intensive Care Units in a Tertiary Care Hospital: An Armor for Refuge, BioMed Res. Int., 2021, 8817700, 10.1155/2021/8817700 · DOI
  24. 2016, Pseudomonas aeruginosa in premise plumbing of large buildings, MicrobiologyOpen, 5, 937, 10.1002/mbo3.391 · DOI · Paper page
  25. Arancibia, 2002, Community-Acquired Pneumonia Due to Gram-Negative Bacteria and Pseudomonas aeruginosa: Incidence, Risk, and Prognosis, Arch. Intern. Med., 162, 1849, 10.1001/archinte.162.16.1849 · DOI · Paper page
  26. Kaier, K., Heister, T., Götting, T., Wolkewitz, M., and Mutters, N. (2019). Measuring the in-hospital costs of Pseudomonas aeruginosa pneumonia: Methodology and results from a German teaching hospital. BMC Infect. Dis., 19. · doi:10.1186/s12879-019-4660-5
  27. Restrepo, 2018, Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients, Eur. Respir. J., 52, 1701190, 10.1183/13993003.01190-2017 · DOI · Paper page
  28. Pressler, 2011, Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report, J. Cyst. Fibros., 10, S75, 10.1016/S1569-1993(11)60011-8 · DOI · Paper page
  29. Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat. Rev. Genet., 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
  30. Rau, 2010, Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts, Environ. Microbiol., 12, 1643, 10.1111/j.1462-2920.2010.02211.x · DOI
  31. 2019, Pseudomonas aeruginosa in cystic fibrosis: A chronic cheater, Proc. Natl. Acad. Sci. USA, 116, 6525, 10.1073/pnas.1902734116 · doi:10.1073/pnas.1902734116
  32. Ehsan, 2015, Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin, Futur. Microbiol., 10, 1901, 10.2217/fmb.15.117 · DOI
  33. Hartl, 2012, Innate immunity in cystic fibrosis lung disease, J. Cyst. Fibros., 11, 363, 10.1016/j.jcf.2012.07.003 · DOI · Paper page
  34. Toledano, 2019, Pseudomonas aeruginosa colonization causes PD-L1 overexpression on monocytes, impairing the adaptive immune response in patients with cystic fibrosis, J. Cyst. Fibros., 18, 630, 10.1016/j.jcf.2018.11.002 · DOI
  35. Costas, 2016, Specific immune response against Pseudomonas aeruginosa and haemophilus influenzae in severe COPD, Eur. Respir. J., 48, OA1790
  36. Kwok, 2021, Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications, Respir. Res., 22, 132, 10.1186/s12931-021-01729-5 · DOI
  37. Fisher, 1970, Vaccination for Pseudomonas aeruginosa, Am. J. Surg., 120, 512, 10.1016/S0002-9610(70)80019-8 · doi:10.1016/s0002-9610(70)80019-8
  38. Young, 1973, Pseudomonas aeruginosa Vaccine in Cancer Patients, Ann. Intern. Med., 79, 518, 10.7326/0003-4819-79-4-518 · doi:10.7326/0003-4819-79-4-518
  39. Pennington, 1974, Preliminary Investigations of Pseudomonas aeruginosa Vaccine in Patients with Leukemia and Cystic Fibrosis, J. Infect. Dis., 130, S159, 10.1093/infdis/130.Supplement.S159 · doi:10.1093/infdis/130.supplement.s159
  40. Pennington, 1975, Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis, Am. J. Med., 58, 629, 10.1016/0002-9343(75)90498-2 · doi:10.1016/0002-9343(75)90498-2
  41. Jones, 1976, A new Pseudomonas vaccine: Preliminary trial on human volunteers, J. Hyg., 76, 429, 10.1017/S0022172400055364 · doi:10.1017/s0022172400055364
  42. Elizabeth, 1983, Immunization of Burned Patients against Pseudomonas aeruginosa Infection at Safdarjang Hospital, New Delhi, Rev. Infect. Dis., 5, S922, 10.1093/clinids/5.Supplement_5.S922 · doi:10.1093/clinids/5.supplement_5.s922
  43. Langford, 1984, Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results, Arch. Dis. Child., 59, 1131, 10.1136/adc.59.12.1131 · doi:10.1136/adc.59.12.1131
  44. Cryz, 1987, Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans, J. Clin. Investig., 80, 51, 10.1172/JCI113062 · doi:10.1172/jci113062
  45. Cryz, 1988, Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: Effect of a booster dose on antibody levels in humans, Infect. Immun., 56, 1829, 10.1128/iai.56.7.1829-1830.1988 · doi:10.1128/iai.56.7.1829-1830.1988
  46. Schaad, 1991, Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis, Lancet, 338, 1236, 10.1016/0140-6736(91)92103-9 · doi:10.1016/0140-6736(91)92103-9
  47. 2010, Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, Int. J. Med Microbiol., 300, 573, 10.1016/j.ijmm.2010.08.010 · doi:10.1016/j.ijmm.2010.08.010
  48. Crowe, 1991, The First Clinical Trial of Immuno’s Experimental Pseudomonas aeruginosa Flagellar Vaccines, Pseudomonas Aeruginosa Hum. Dis., 44, 143
  49. Pfeiffer, 1995, Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals, Am. J. Respir. Crit. Care Med., 151, 983
  50. Meisner, 2007, For the Flagella Vaccine Trial Study Group A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, Proc. Natl. Acad. Sci. USA, 104, 11020, 10.1073/pnas.0702403104 · DOI · Paper page
  51. Pier, 1994, Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine, Infect. Immun., 62, 3972, 10.1128/iai.62.9.3972-3979.1994 · DOI
  52. Cripps, 1997, Vaccine strategies against Pseudomonas aeruginosa infection in the lung, Behring Inst. Mitt., 98, 262
  53. Cripps, 2006, Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects, Infect. Immun., 74, 968, 10.1128/IAI.74.2.968-974.2006 · doi:10.1128/iai.74.2.968-974.2006
  54. Mansouri, 1999, Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers, Infect. Immun., 67, 1461, 10.1128/IAI.67.3.1461-1470.1999 · DOI
  55. Mansouri, 2003, Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients, FEM Immunol. Med. Microbiol., 37, 161, 10.1016/S0928-8244(03)00072-5 · doi:10.1016/s0928-8244(03)00072-5
  56. Westritschnig, 2014, A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers, Hum. Vaccines Immunother., 10, 170, 10.4161/hv.26565 · DOI
  57. Rello, 2017, A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients, Crit. Care, 21, 22, 10.1186/s13054-017-1601-9 · DOI
  58. Adlbrecht, 2020, Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial, Crit. Care, 24, 74, 10.1186/s13054-020-2792-z · doi:10.1186/s13054-020-2792-z
  59. Larbig, 2001, Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers, Vaccine, 19, 2291, 10.1016/S0264-410X(00)00550-8 · DOI
  60. Baumann, 2003, Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule, FEMS Immunol. Med. Microbiol., 37, 167, 10.1016/S0928-8244(03)00094-4 · DOI
  61. Baumann, 2007, Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: A clinical phase I/II study, Respir. Res., 8, 57, 10.1186/1465-9921-8-57 · DOI
  62. Lang, 2004, Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection, Pediatr. Infect. Dis. J., 23, 504, 10.1097/01.inf.0000129688.50588.ac · DOI
  63. Zuercher, 2006, Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine, Clin. Exp. Immunol., 142, 381, 10.1111/j.1365-2249.2005.02925.x · doi:10.1111/j.1365-2249.2005.02925.x
  64. Pier, 1987, Opsonophagocytic Killing Antibody to Pseudomonas aeruginosa Mucoid Exopolysaccharide in Older Noncolonized Patients with Cystic Fibrosis, N. Engl. J. Med., 317, 793, 10.1056/NEJM198709243171303 · doi:10.1056/nejm198709243171303
  65. Meluleni, 1995, Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients, J. Immunol., 155, 2029, 10.4049/jimmunol.155.4.2029 · DOI
  66. Mutharia, 1983, Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies, Infect. Immun., 42, 1027, 10.1128/iai.42.3.1027-1033.1983 · DOI
  67. Knapp, 1995, Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins, Infect. Immun., 63, 1855, 10.1128/iai.63.5.1855-1862.1995 · doi:10.1128/iai.63.5.1855-1862.1995
  68. Gabelsberger, 2000, Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections, J. Biotechnol., 83, 3, 10.1016/S0168-1656(00)00311-4 · doi:10.1016/s0168-1656(00)00311-4
  69. Kaye, 2015, Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management, Pharmacother. J. Hum. Pharmacol. Drug Ther., 35, 949, 10.1002/phar.1636 · DOI · Paper page
  70. Sorichter, 2009, Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease, Vaccine, 27, 2755, 10.1016/j.vaccine.2009.03.010 · DOI
  71. Sainz-Mejías, M., Jurado-Martín, I., and McClean, S. (2020). Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine. Cells, 9. · DOI
  72. Baker, 2020, Immunological considerations in the development of Pseudomonas aeruginosa vaccines, Hum. Vaccines Immunother., 16, 412, 10.1080/21645515.2019.1650999 · DOI
  73. Lavoie, 2011, Innate immune responses to Pseudomonas aeruginosa infection, Microbes Infect., 13, 1133, 10.1016/j.micinf.2011.07.011 · DOI · Paper page
  74. Mauch, 2018, Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis, J. Cyst. Fibros., 17, 143, 10.1016/j.jcf.2017.08.012 · DOI
  75. McIsaac, 2012, Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis, J. Leukoc. Biol., 92, 977, 10.1189/jlb.0811410 · DOI
  76. Lin, 2017, Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection, J. Innate Immun., 9, 250, 10.1159/000455857 · DOI
  77. Jensen, 1993, Complement activation by Pseudomonas aeruginosa biofilms, Microb. Pathog., 15, 377, 10.1006/mpat.1993.1087 · doi:10.1006/mpat.1993.1087
  78. Johansen, 2004, Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: A marker of therapeutic success?—A 30-year Cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection, Pediatric Pulmonol., 37, 427, 10.1002/ppul.10457 · DOI
  79. Jones, 2003, Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa, Eur. Respir. J., 22, 503, 10.1183/09031936.03.00004503 · DOI
  80. Hellfritzsch, M., and Scherließ, R. (2019). Mucosal Vaccination via the Respiratory Tract. Pharmaceutics, 11. · DOI
  81. Lavelle, 2022, Mucosal vaccines—Fortifying the frontiers, Nat. Rev. Immunol., 22, 236, 10.1038/s41577-021-00583-2 · DOI · Paper page
  82. Fan, 2019, Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids, Int. Immunopharmacol., 69, 389, 10.1016/j.intimp.2019.01.055 · DOI
  83. Ma, 2021, A novel inactivated whole-cell Pseudomonas aeruginosa vaccine that acts through the cGAS-STING pathway, Signal Transduct. Target. Ther., 6, 353, 10.1038/s41392-021-00752-8 · DOI
  84. Meynet, 2018, Killed but metabolically active Pseudomonas aeruginosa -based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections, Vaccine, 36, 1893, 10.1016/j.vaccine.2018.02.040 · doi:10.1016/j.vaccine.2018.02.040
  85. Jing, 2020, Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection, Int. J. Biol. Macromol., 159, 174, 10.1016/j.ijbiomac.2020.05.057 · DOI
  86. Ding, 2010, OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa, Vaccine, 28, 4119, 10.1016/j.vaccine.2010.04.028 · doi:10.1016/j.vaccine.2010.04.028
  87. Kiyono, H., and Pascual, D.W. (2020). Mucosal Vaccines, Academic Press. [2nd ed.].
  88. Moyle, 2013, Modern Subunit Vaccines: Development, Components, and Research Opportunities, ChemMedChem, 8, 360, 10.1002/cmdc.201200487 · DOI · Paper page
  89. Moxon, 2019, Editorial: Reverse Vaccinology, Front. Immunol., 10, 2776, 10.3389/fimmu.2019.02776 · doi:10.3389/fimmu.2019.02776
  90. Rashid, 2017, Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach, Genomics, 109, 274, 10.1016/j.ygeno.2017.05.001 · DOI
  91. Bianconi, 2019, Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa, Front. Immunol., 9, 3021, 10.3389/fimmu.2018.03021 · DOI
  92. Day, 2019, Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54, Biochem. Biophys. Res. Commun., 513, 287, 10.1016/j.bbrc.2019.03.092 · DOI
  93. Solanki, 2019, Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa, Sci. Rep., 9, 5240, 10.1038/s41598-019-41496-4 · DOI
  94. Wu, 2012, Th17-stimulating Protein Vaccines Confer Protection against Pseudomonas aeruginosa Pneumonia, Am. J. Respir. Crit. Care Med., 186, 420, 10.1164/rccm.201202-0182OC · DOI
  95. Mall, 2008, Role of Cilia, Mucus, and Airway Surface Liquid in Mucociliary Dysfunction: Lessons from Mouse Models, J. Aerosol Med. Pulm. Drug Deliv., 21, 13, 10.1089/jamp.2007.0659 · DOI · Paper page
  96. Baker, 2019, Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia, Vaccine, 37, 808, 10.1016/j.vaccine.2018.12.053 · DOI
  97. Das, 2020, Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa, Front. Immunol., 11, 583008, 10.3389/fimmu.2020.583008 · DOI
  98. Gbian, D., and Omri, A. (2021). The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against Pseudomonas aeruginosa. Pharmaceutics, 13. · doi:10.3390/pharmaceutics13040577
  99. Solleti, 2015, Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients, J. Antimicrob. Chemother., 70, 784, 10.1093/jac/dku452 · DOI
  100. Heurtault, 2009, Design of a Liposomal Candidate Vaccine Against Pseudomonas aeruginosa and its Evaluation in Triggering Systemic and Lung Mucosal Immunity, Pharm. Res., 26, 276, 10.1007/s11095-008-9724-y · DOI
  101. Mayeux, 2021, Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes, Life Sci. Alliance, 4, e202000958, 10.26508/lsa.202000958 · DOI
  102. 2010, Naturally Produced Outer Membrane Vesicles from Pseudomonas aeruginosa Elicit a Potent Innate Immune Response via Combined Sensing of Both Lipopolysaccharide and Protein Components, Infect. Immun., 78, 3822, 10.1128/IAI.00433-10 · DOI · Paper page
  103. Li, 2021, Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection, mSphere, 6, e00699-21, 10.1128/mSphere.00699-21 · doi:10.1128/msphere.00699-21
  104. Li, 2021, Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection, Infect. Immun., 89, IAI0039621, 10.1128/IAI.00396-21 · DOI
  105. Micoli, 2020, Outer membrane vesicle vaccines, Semin. Immunol., 50, 101433, 10.1016/j.smim.2020.101433 · DOI · Paper page
  106. Bumann, 2010, Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers, Vaccine, 28, 707, 10.1016/j.vaccine.2009.10.080 · doi:10.1016/j.vaccine.2009.10.080
  107. Zhang, 2015, Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa, Microbiol. Immunol., 59, 533, 10.1111/1348-0421.12291 · doi:10.1111/1348-0421.12291
  108. McConnell, 2019, A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa, mSphere, 4, e00116-19, 10.1128/mSphere.00116-19 · doi:10.1128/msphere.00116-19
  109. Chen, H., Ji, H., Kong, X., Lei, P., Yang, Q., Wu, W., Jin, L., and Sun, D. (2021). Bacterial Ghosts-Based Vaccine and Drug Delivery Systems. Pharmaceutics, 13. · DOI
  110. Sheweita, S.A., Amara, A.A., Gamal, H., Ghazy, A.A., Hussein, A., and Bahey-El-Din, M. (2022). Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats. Vaccines, 10. · doi:10.3390/vaccines10060910
  111. Rodgers, 2018, Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: A proof of concept study, Int. J. Pharm., 549, 87, 10.1016/j.ijpharm.2018.07.049 · doi:10.1016/j.ijpharm.2018.07.049
  112. Cui, 2015, Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity, Appl. Microbiol. Biotechnol., 99, 667, 10.1007/s00253-014-6147-z · doi:10.1007/s00253-014-6147-z
  113. Najafzadeh, 2021, Immunological Properties of Exotoxin A Toxoid—Detoxified Lipopolysaccharide—Gold Nanoparticles Conjugate Against Pseudomonas aeruginosa Infection, Iran. J. Immunol., 18, 292
  114. Chen, 2018, Aluminum (oxy) Hydroxide Nanorods Activate an Early Immune Response in Pseudomonas aeruginosa Vaccine, ACS Appl. Mater. Interfaces, 10, 43533, 10.1021/acsami.8b18164 · doi:10.1021/acsami.8b18164
  115. Howlader, 2021, Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas aeruginosa, Front. Pharmacol., 12, 2137, 10.3389/fphar.2021.706157 · doi:10.3389/fphar.2021.706157
  116. Shapouri, 2019, Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: Protectivity in murine model, World J. Microbiol. Biotechnol., 35, 94, 10.1007/s11274-019-2669-y · DOI
  117. Azimi, 2021, Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine, Iran. J. Basic Med Sci., 24, 476
  118. Gonzaga, 2022, Intranasal Delivery of Antigen-Coated Polymer Particles Protects against Pseudomonas aeruginosa Infection, ACS Infect. Dis., 8, 744, 10.1021/acsinfecdis.1c00434 · DOI

Cited by

See all 93

Metadata

Authors
Killough, M., Rodgers, A., & Ingram, R.
Venue
Vaccines
Publisher
MDPI AG
Published
2022-07-08
Volume
10
Issue
7
Pages
1100
ISSN
2076-393X
Cited by
93
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pseudomonas aeruginosa: Recent Advances in Vaccine Development. https://app.cochat.ai/papers/10.3390/vaccines10071100
The paper
Killough, M., Rodgers, A., & Ingram, R. (2022). Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines. https://doi.org/10.3390/vaccines10071100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.